Unjha Formul. (531762)
Score breakdown: P/E: 3/3 · ROCE: 1/2 · Growth: 1/2 · Dividend: 0/1
Key Financials
| Current Price | ₹21.6 |
| Market Cap | ₹10 Cr |
| P/E Ratio | 9.35 |
| ROCE | 18.06% |
| ROE | 31.39% |
| Dividend Yield | 0% |
| Profit Growth | 9.09% |
| Debt/Equity | — |
| Sales Growth | 17.29% |
| 52-Week Range | ₹18.6 — ₹27.8 |
| Sector | Pharmaceuticals & Biotechnology |
| Book Value | ₹7.92 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
As a value investor, I first ask what I actually own. Unjha Formul. is a ₹10 Cr microcap pharmaceutical company. At ₹21.60, I am paying 9.35 times earnings and 2.73 times book value. The 31.39% return on equity is eye-catching, but Graham would remind me that a high ROE without a durable moat is often a small company's temporary advantage. A book value of ₹7.92 gives me some asset floor, but at 2.73 times book, the price is not a distress bargain. Debt/Equity is not disclosed, so I cannot fully assess the balance-sheet risk. That absence of data bothers me more than a high debt number would.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer